Dr. Mosavi-Jarrahi received his Ph.D. in epidemiology from the University of Texas in 1996. Upon graduation, He began his post-doctoral research at the University of Texas Health Science Center. In 1998, he joined the Cancer Institute in Tehran, Iran, working as a research associate and at the same time he received a joint appointment as an assistant professor at the Medical School, Shahid Beheshti University of Medical Sciences Tehran, Iran. In 2011, he joined the Faculty of Health Sciences (FHS), Simon Fraser University as an adjunct professor of epidemiology. He has published more than 60 papers in peer-reviewed journals and received several grants from different funding agencies such as Terry Fox Foundation (international), World Health Organization. He is a founding member of the Iranian Epidemiological Association and served as its first general secretary for two terms. He is a member of many scientific journals’ editorial board. In July 2016, he was appointed as the Editor-in-Chief of the Asia Pacific Journal of Cancer Prevention.  In April 2018, Dr. Mosavi Jarrah was elected as the President of Asian Pacific Organization for Cancer Prevention (APOCP) for a duration of two years.

Professor David Roder joined The University of South Australia in 2011 as Professor of Cancer Epidemiology within the Sansom Institute for Health Research. His previous role was with the Cancer Council South Australia where he headed the research section. He has been a specialist epidemiology consultant to: the NSW Cancer Institute (since 2004); the former National Breast and Ovarian Cancer Centre (since 2005); and Cancer Australia (since 2007). As well as international consultancies with WHO in Mongolia, Malaysia and Indonesia, and consultant to the Malaysian and New Zealand Governments.
Professor Roder presently Chairs the National Cervical Cancer Safety Monitoring Committee, the Biostatistics Collaboration of Australia Advisory Committee, the Clinical Quality Registry Advisory Committee of the Australian Commission on Safety and Quality in Health Care, the Cross-jurisdictional Steering Committee of the WA Data Linkage System, and has been a member of the National Quality and Management Committee of BreastScreen Australia since 1995. 
He has authored approximately 200 peer-reviewed research publications and has been an invited presenter of scientific papers and/or chaired sessions at international scientific meetings in Australia, NZ, the UK, USA, Africa, NZ, Mongolia, Japan and a number of South East Asian countries. His influence in the area of health was recognised in 2000 with the Member of the Order of Australia award for contributions to cancer epidemiology, cancer registration and research.

He is a medical doctor specializing in radiation oncology with interest in Preventive Oncology. He has obtained Fellowship from NCI/NIH in cancer control and molecular prevention in cancer. 

Dr. Niveen Abu-Rmeileh is an Associate Professor of Statistical Epidemiology and the Director of the Institute of Community and Public Health at Birzeit University. Dr. Abu-Rmeileh holds a BSc in Medical Technology , a Master in Public Health and a PhD in Statistical Epidemiology from University of Glasgow. She teaches a variety of courses on quantitative research methods, health statistics and population studies. Her research interest is focused on the three broad categories: epidemiology of chronic diseases, reproductive health, and building psychometrics. More about Dr. Nivin Abu-Rmeileh click here..

Dr. Shahab Uddin is a Senior Scientist and Head of Molecular Pathophysiology, at Transnational Research Institute, Hamad Medical Corporation, Doha, Qatar. He graduated with BSc. Degree in Chemistry from the Aligarh Muslim University, India in 1982. He then received his MSc, MPhil and Ph.D. degrees in Biochemistry from Aligarh Muslim University, India in 1984, 1986 and 1988 respectively. After completing his graduate degree, he joined the Ohio State University, Columbus, USA for postdoctoral training for two years (1989-1991). He worked in the area molecular biology of DNA. He joined Loyola University of Chicago, Illinois, USA, and worked from April1991-1995 under Molecular Biology Training Program. He received extensive training in the molecular biology of brain hormone as well signaling mechanism of interferon in leukemia. In 1996, he joined the University of Illinois at Chicago initially as Instructor and then as Research Assistant Professor in the Department of Medicine. He continued working in the area of interferon signaling.  He joined the University of Chicago as Research Associate Professor and worked till 2003. In 2003, he joined King Faisal Specialist Hospital & Research Centre, Riyadh, KSA, as a Scientist initially (2003-2005) and subsequently promoted to Senior Scientist (2005) and deputy director of Human Cancer Genomic Program. Dr. Shahab contributed to the establishment of Human Cancer Genomic Program at King Faisal Specialist Hospital & Research Centre for translational research.   Currently, he is working as Senior Scientist and Head of Molecular Pathophysiology section in interim Translational Research Institute at Hamad Medical Corporation, Doha, Qatar. 

The primary research interest of Dr. Shahab is to identify dysregulated signaling molecular that are involved in survival and proliferation of malignant cells.  These molecular targets, once identified, will be helpful in the prognostic marker for detection of the onset of malignancy. On the other hand, these molecules will also serve as an attractive target for targeted therapy for the treatment and management of cancer cells.

Dr. Shahab Uddin published over 190 peer-reviewed articles in high impact factor journal such as Journal of Biological Chemistry, PNAS, Blood, Cancer Research, Journal of Immunology, and Clinical Cancer Research.  He has trained numerous postdoctoral fellows, Medical fellows, and graduate students. He has supervised numerous scientists, technicians, and students of different levels. He has served numerous scientific and administrative committees. He has been consciously reviewing manuscripts and grants proposals of international journal and agencies respectively.   

Dr Abu-Helalah is currently the Middle East, North Africa & Central Asia, Regions Director for Global Academy for Health Sciences, Ohio, USA and Adjunct Associate Professor of Epidemiology and Preventive Medicine, College of Medicine AlFaisal University, KSA.

Dr Abu-Helalah completed his medical degree from Jordan University of Science and Technology (JUST) 2001. He moved in 2002 to the United Kingdom (UK) where completed a master degree in Public Health (MPH) from the University of Dundee in 2004 and a PhD in epidemiology and preventive medicine from the University of London in 2009. While he was in the UK, he worked as a Research Fellow in epidemiology and preventive Medicine at the St Bartholomew’s Hospital, London-UK, in 2007/2008.

In 2009, he joined King Hussein Cancer Center in Jordan as a Senior Officer for the cancer control program. In 2011, he joined the National Guard Health affairs as an Assistant Professor of Epidemiology and Preventive Medicine. In February 2012, he returned to work in Jordan at the Faculty of Medicine, Mutah University. In February 2016, he received an early promotion to be an Associate Professor of Epidemiology and Preventive Medicine. He was selected in 2013 as the regional director for the Global Center for Public Health and Disease Control. In 1 June 2016, he move to the Global Academy for Health Sciences, Ohio, USA as the Regional Director for the Middle East, North Africa and Central Asia regions Director. Since 1 September 2017, he joined AlFaisal University, KSA as an Adjunct Associate Professor in Epidemiology and Preventive Medicine. He also works as a consultant and technical expert for several regional and international organizations.
Dr Abu-Helalah has special expertise and interest in chronic diseases control and prevention particularly cancer, diabetes, thyroid disorders, cardiovascular diseases, medical research, and smoking cessation. he has had more than 30 publications in these fields in peer-reviewed journals and directed many scientific meetings in these fields.

On 9 April 2014, Dr Abu-Helalah was honoured by HRH Prince of Eastern Region, KSA, Prince Saud Bin Nayef, as the “Winner of the First place in the Prince of Easter Region Award for the Best Cancer Research in the Arab World” in the first round of this prize.

Dr. Omran S. Habib is Professor of epidemiology and health care at Department of Community Medicine, College of Medicine, University of Basrah, Basrah, Iraq. He has been teaching both undergraduate and postgraduate students and doing scientific research plus actively being involved in public health consultancy. He has served as a member of several national and international organizations such as Council of Community Medicine and Family Medicine (Iraq), Iraqi Cancer Board (2008-2015), Iraqi Medical association since 1977, Iraqi Union of teachers since 1977, the editorial board of the Asian Pacific Journal of Cancer prevention. He has punished numerous research papers and books throughout his career.

Mehrnoosh Doroudchi received her Masters Degree as the top student among her peers in Medical Microbiology from Shiraz University of Medical Sciences (SUMS) in 1994. She was awarded her PhD in Immunology at SUMS in 1999 and She immediately started her work as an assistant professor in the Department of Immunology in School of Medicine, SUMS, where she committed her research to biomarkers in cancer research and inflammation. She joined the Laboratory of professor R.P. Sekaly in University of Montreal, Canada in a research fellowship program between 2005-2008 where she researched memory T cells. Since her return to the Department of Immunology as an associate professor, she has devoted her laboratory to research on T cells in inflammatory diseases and cancer as well as continuing study on biomarkers. As one of the trustee members of Shiraz Institute for Cancer Research, Mehrnoosh Doroudchi has made contributions in Cancer Biomarker research through multiple publications in high ranked journals in the field. She has supervised numerous Masters, Ph.D. and Medical specialty theses in the field of cancer in Iran to enhance education on the subject among graduates of medical school in Shiraz, Iran. She has also been serving as an associate editor in the Iranian Journal of Immunology since 2004.

Prof. Makvandi is the head of virology of deprtment in Ahwaz University of Medical Sciences, Ahwaz Iran. In addition he serve as the chief  of virology laboratory for diagnosis of measles, rubella and influenza viruses  in the south region of Iran, comission from the Iranian Ministry of Health and Medical Education since 1990 .

My educational and research background has provided me with expertise in Oncology,
Microbiology, and Molecular Biology. This knowledge enables me to plan and execute research projects aimed at uncovering disease mechanisms and implementing treatments in preclinical models of infectious and metabolic diseases. My focus is on developing innovative therapeutic methods. I have hands-on experience in working with these disease models, translating scientific discoveries into practical applications. Overall, my diverse skill set, and practical experience allow me to bridge the gap between scientific knowledge and real-world solutions, with the ultimate goal of improving disease understanding and treatment for the benefit of society.

Prof Ravi Mehrotra is a Member of the Scientific Council of WHO-IARC. He holds an Adjunct Professorship of Epidemiology at the Emory, Brunel and York Universities. Earlier he has been the CEO of the ICMR_ICRC and also directed the ICMR-National Institute of Cancer Prevention and Research as well as the WHO-FCTC Global Hub on Smokeless Tobacco. In addition to Armed Forces Medical College and  Allahabad Univ., he has trained at the Royal College of Pathology, Johns Hopkins and Pennsylvania Universities. 

Dr. Pratheeshkumar Poyil is an Associate Scientist at Human Cancer Genomics research, King Faisal Specialist Hospital and Research Centre (KFSH&RC) Riyadh, Saudi Arabia. Before joining at KFSH&RC, he was a Research Associate in the Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, USA for a period of 2011- 2016. He received his PhD degree in Tumor Immunology from Mahatma Gandhi University in 2011. He has been an author or co-author of more than 58 published research articles including reviews and book chapters; these articles have received 1448 citations with an H-index of 23 (Google Scholar, up to December 25, 2017). Add to this, he is an active reviewer of more than 20 international research journals. He is a member of editorial boards of International Journals and served as guest editor for 4 special journal issues in his research area. He is a highly motivated and innovative molecular biologist expertise in development and execution of translational biology, genetic and biochemistry-based research methods. His research interest includes the elucidation of cancer chemo-resistance mechanisms; identification of novel therapeutic targets in breast, papillary thyroid, colon and ovarian cancers and their targeting with small molecule inhibitors.

Dr Bhat is currently working as a research scientist at Dept. of Translational Medicine, Sidra Medicine, Qatar. He completed his PhD from one of the premier institutes (All India Institute of Medical Sciences, AIIMS) in India. During Ph.D., he carried his reaserch on “Development of peptide based vaccine for Malraia, HIV and plague using immunoadjuvants and novel delivery vehicles”. After his Ph.D., he moved to Vanderbilt University Medical School, Nashville, TN, the USA for a postdoctoral fellowship.  During his eight years of postdoctoral training at Vanderbilt, he has gained broad experience in the field of cancer biology. His focus of the research was on the role and regulation of tight junction proteins (Claudins) in colorectal cancer and the role of bile acid-induced APE1/Ref1 in esophageal adenocarcinoma. He has published in well-reputed journals like Nature Communications, GUT, Oncogene, Cancer Research, Molecular Cancer and many more enlisted in his CV. He has attended many international meetings, conferences, symposia to present his research results. He has been awarded from Immunology society and American Association of Cancer research. He has also been awarded as an outstanding researcher for the year 2018 and 2019 from Sidra Medicine. He is an active member of many immunological and cancer societies. He is also serving in the editorial board and review committee of many journals.

Dr. Gultekin is a Gynae Oncologist, an associated Professor and lately a government official, who is actively involved in several leading cancer organizations, such as a council member of the European Society of Gynaecological Oncology (ESGO) and the International Agency for Research on Cancer (IARC) as well as a board member of the Middle East Cancer Consortium, Black Sea Countries Coalition on Breast and Cervical Carcinoma, Women Against Cervical Cancers (WACC), Asian Pacific Organization for Cancer Prevention and Asian National Cancer Centers Alliance (ANCCA). 
Furthermore, Dr. Gultekin has conducted several Pan-European oncology trials and is engaged in collaboration projects with the World Health Organization (WHO), International Agency for Research on Cancer(IARC), American Cancer Society (ACS) and American Society of Clinical Oncologist (ASCO).
As a member of the Turkish Society of Gynaecological Oncology, Dr. Gultekin officially represents the society on foreign affairs and urged the recognition of gynaecological oncology as a subspecialty in Turkey. 

Dr. Farzad Taghizadeh-Hesary is a board-certified of Radiation Oncology from Iran. He achieved his MD degree from Iran University of Medical Sciences (IUMS) in 2015 with an Exceptional-talent degree from the Ministry of Health. Subsequently, he passed the specialist course in Radiation Oncology at Shahid Beheshti University of Medical Sciences (SBMU) between 2015 and 2019 and achieved fourth place in the Radiation Oncology Board examination. He has authored approximately 20 peer-reviewed research publications and has reviewed approximately 100 manuscripts for ISI and Scopus indexed journals. Now, he is the Academic Editor of “Medicine ®“ and Associate editor of the “Asian Pacific Journal of Cancer Prevention”. Farzad and his group research on basic concepts of oncology. Their current project is the effect of mitochondria on cancer biogenesis and treatment.

Dr. Alisher Kahharov, MD, PhD, is a leading oncologist specializing in breast cancer, with a strong focus on cancer education and research. He holds a Doctor of Science degree and has served as an Associate Professor of Oncology and the medical radiology department of Tashkent State Dental Institute. Dr. Kahharov is a dedicated ESO Ambassador, actively involved in improving oncology education across Central Asia. His research and publications have significantly contributed to the understanding of breast cancer diagnostics and treatment. He has held various leadership roles in prominent oncology institutions in Uzbekistan.